Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Addiction. 2023 Nov;118(11):2193-2202. doi: 10.1111/add.16301. Epub 2023 Jul 25.
To estimate the joint effects of substance use disorder (SUD) and recent substance use on human immunodeficiency virus (HIV) non-suppression.
Retrospective clinical cohort study with repeated observations within individuals.
Baltimore, Maryland, United States.
1881 patients contributed 10 794 observations.
The primary independent variable was the combination of history of SUD and recent substance use. History of SUD was defined as any prior International Classification of Diseases 9/10 code for cocaine or opioid disorder. Recent substance use was defined as the self-report of cocaine or non-prescribed opioid use on the National Institute of Drug Abuse-modified Alcohol, Smoking and Substance Involvement Screening Test or clinician-documented cocaine or opioid use abstracted from the medical record. The outcome was viral non-suppression, defined as HIV RNA >200 copies/mL on the first viral load measurement within 1 year subsequent to each observation of substance use. We adjusted for birth sex, Black race, age, HIV acquisition risk factors, years in care and CD4 cell count. In secondary analyses, we also adjusted for depressive, anxiety and panic symptoms, cannabis use and cannabis use disorder.
On their first observation, 31% of patients had a history of an SUD and 18% had recent substance use. Relative to no history of SUD and no recent substance use, the 1-year fully adjusted risk difference (RD) for viral non-suppression associated with cocaine and opioid use disorder and recent substance use was 7.7% (95% CI = 5.3%-10.0%), the RD was 5.5% (95% CI = 1.2%-9.7%) for history of cocaine use disorder without recent substance use, and the RD was 4.6% (95% CI = 2.7%-6.5%) for recent substance use without a SUD.
Substance use and substance use disorders appear to be highly prevalent among, and independently associated with, viral non-suppression among people with HIV.
评估物质使用障碍(SUD)和近期物质使用对人类免疫缺陷病毒(HIV)未抑制的联合影响。
个体内重复观察的回顾性临床队列研究。
美国马里兰州巴尔的摩市。
1881 名患者共贡献了 10794 次观察。
主要的独立变量是物质使用障碍史和近期物质使用的组合。物质使用障碍史定义为国际疾病分类第 9/10 版中任何可卡因或阿片类物质障碍的既往编码。近期物质使用定义为在国家药物滥用研究所修改的酒精、吸烟和物质参与筛查测试中自我报告可卡因或非处方阿片类药物使用,或从医疗记录中提取的临床医生记录的可卡因或阿片类药物使用。结果是病毒未抑制,定义为每次观察物质使用后 1 年内首次病毒载量测量时 HIV RNA >200 拷贝/ml。我们调整了出生性别、黑人种族、年龄、HIV 获得风险因素、在护理中的年数和 CD4 细胞计数。在二次分析中,我们还调整了抑郁、焦虑和惊恐症状、大麻使用和大麻使用障碍。
在他们的第一次观察中,31%的患者有物质使用障碍史,18%的患者有近期物质使用。与无物质使用障碍史和无近期物质使用相比,可卡因和阿片类物质使用障碍和近期物质使用与病毒未抑制相关的 1 年全调整风险差异(RD)为 7.7%(95%CI=5.3%-10.0%),有可卡因使用障碍但无近期物质使用的 RD 为 5.5%(95%CI=1.2%-9.7%),近期物质使用但无物质使用障碍的 RD 为 4.6%(95%CI=2.7%-6.5%)。
物质使用和物质使用障碍在 HIV 感染者中似乎非常普遍,并且与病毒未抑制独立相关。